CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Pomalidomide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01665794
NCT01665794Phase 2Completed
CompareCT.gov

Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

University of Chicago·interventional·Posted Aug 15, 2012·Updated Dec 22, 2025

In Brief

A Phase 2 clinical trial evaluating Pomalidomide, Carfilzomib, and 2 other interventions for Multiple Myeloma. Completed, enrolled 25 participants across 5 sites in 2 countries.

Detailed Summary

The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesCanada, United States
CollaboratorsNational Cancer Institute (NCI), Multiple Myeloma Research Foundation

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 15, 2012
Enrollment StartAug 13, 2012
Primary CompletionNov 14, 2025
TodayJul 2, 2026
Enrollment to primary: 13.3 yearsPosted 13.9 years ago

Interventions

Pomalidomidedrug

Pomalidomide taken orally at assigned dose.

Carfilzomibdrug

Carfilzomib given by intravenous (IV) infusion at assigned dose.

dexamethasonedrug

Dexamethasone taken orally of given by IV infusion.

Daratumumabdrug

Daratumumab given by intravenous (IV) infusion at assigned dose.